Market Overview

Vertex Pharma's Earnings Preview

Related VRTX
Proteostasis Tumbles 25% After Short Seller Calls Leading Drug Candidate 'A Dud'
Baird: Prospects For Proteostasis Therapeutics' PTI-428 Are Not Priced Into The Stock
Proteostasis Therapeutics' FDA Breakthrough Therapy Designation Gives It An Edge (Seeking Alpha)

Vertex Pharmaceuticals (NASDAQ: VRTX) releases its next round of earnings Monday, Jan. 8. Here's Benzinga's essential guide to Vertex's Q4 earnings report.

Earnings and Revenue

Based on Vertex management projections, analysts predict EPS of 53 cents on revenue of $594 million.

In the same quarter last year, Vertex Pharmaceuticals reported earnings per share of 13 cents on revenue of $458 million. The current analyst consensus estimate would represent a 51.43 percent increase in the company's earnings. Sales would be up 29.59 percent on a year-over-year basis. The company's reported EPS has stacked up against analyst estimates in the past like this:

Quarter Q3 2017 Q2 2017 Q1 2017 Q4 2016
EPS Estimate 0.3 0.35 1.2 0.29
EPS Actual 0.53 0.39 0.41 0.35


Q4 EPS Estimate: 0.53
Q4 Revenues Estimate: $594 million

Stock Performance

Shares of Vertex were trading at $155.99 as of Monday morning. Over the last 52-week period, shares are up 96.93 percent. Given that these returns are generally positive, long-term shareholders are probably satisfied going into this earnings release.

Over the past 90 days, analysts have generally adjusted their estimates higher for EPS and revenues. The average rating by analysts on Vertex stock is a Neutral. The strength of this rating has maintained conviction over the past ninety days.

Conference Call

Vertex Pharmaceuticals's Q4 is scheduled to hold a conference call at 4 p.m. ET.

Posted-In: Earnings News Previews Trading Ideas


Related Articles (VRTX)

View Comments and Join the Discussion!